khs101 has been researched along with Glioblastoma* in 2 studies
2 other study(ies) available for khs101 and Glioblastoma
Article | Year |
---|---|
Discovery of novel analogs of KHS101 as transforming acidic coiled coil containing protein 3 (TACC3) inhibitors for the treatment of glioblastoma.
Transforming acidic coiled coil containing protein 3 (TACC3) is emerging as an attractive anticancer target in recent years, however, few TACC3 small-molecular inhibitors have been reported up to now. In this study, fifteen compounds were designed and synthesized based on the lead compound KHS101 to find more potent TACC3 inhibitors. Among them, the most potent compound 7g exhibited about 10-folds more potent antiproliferative activities than KHS101 in various cancer cell lines. Two different protein-drug binding assays including DARTS, and CETSA revealed TACC3 as a biologically relevant target of compound 7g. In addition, compound 7g induced cell cycle arrest at the G2/M phase and induced cell apoptosis. Furthermore, compound 7g depolarized the MMP and induced ROS generation in a dose-dependent manner in U87 cells. More importantly, 7g reduced tumor weight by 72.7% in U87 xenograft model at a dose of 20 mg/kg/day without obvious toxicity. Altogether, compound 7g deserved further investigations as a novel, safe and efficacious TACC3 inhibitor for the treatment of GBM. Topics: Cell Cycle Proteins; Glioblastoma; Humans; Microtubule-Associated Proteins; Thiazoles | 2022 |
KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice.
Pharmacological inhibition of uncontrolled cell growth with small-molecule inhibitors is a potential strategy for treating glioblastoma multiforme (GBM), the most malignant primary brain cancer. We showed that the synthetic small-molecule KHS101 promoted tumor cell death in diverse GBM cell models, independent of their tumor subtype, and without affecting the viability of noncancerous brain cell lines. KHS101 exerted cytotoxic effects by disrupting the mitochondrial chaperone heat shock protein family D member 1 (HSPD1). In GBM cells, KHS101 promoted aggregation of proteins regulating mitochondrial integrity and energy metabolism. Mitochondrial bioenergetic capacity and glycolytic activity were selectively impaired in KHS101-treated GBM cells. In two intracranial patient-derived xenograft tumor models in mice, systemic administration of KHS101 reduced tumor growth and increased survival without discernible side effects. These findings suggest that targeting of HSPD1-dependent metabolic pathways might be an effective strategy for treating GBM. Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chaperonin 60; Citric Acid Cycle; Disease Models, Animal; Energy Metabolism; Glioblastoma; Glycolysis; Humans; Metabolic Networks and Pathways; Mitochondria; Mitochondrial Proteins; Neoplasm Invasiveness; Stress, Physiological; Survival Analysis; Thiazoles; Transcription, Genetic; Xenograft Model Antitumor Assays | 2018 |